Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


(Plasmid #37852)


Item Catalog # Description Quantity Price (USD)
Plasmid 37852 Standard format: Plasmid sent in bacteria as agar stab 1 $85

This material is available to academics and nonprofits only.


  • Vector backbone
  • Backbone manufacturer
  • Backbone size w/o insert (bp) 5010
  • Total vector size (bp) 5098
  • Vector type

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
  • Growth Strain(s)
  • Copy number


  • Gene/Insert name
    3 copies of ERRE/ERE upstream of luciferase
  • Species
    codon-modified firefly (Photinus pyralis)
  • Insert Size (bp)
  • Promoter SV40

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site KpnI (not destroyed)
  • 3′ cloning site BglII (not destroyed)
  • 5′ sequencing primer RVprimer3
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    3xERRE/ERE-luciferase was a gift from Rebecca Riggins (Addgene plasmid # 37852 ; ; RRID:Addgene_37852)
  • For your References section:

    ERK/MAPK regulates ERRgamma expression, transcriptional activity, and receptor-mediated Tamoxifen resistance in ER+ breast cancer. Heckler MM, Thakor H, Schafer CC, Riggins RB. FEBS J. 2014 Mar 29. doi: 10.1111/febs.12797. 10.1111/febs.12797 PubMed 24684682